Comparison of the VEGF-mediated Egr-1 and Egr-3 expression signals
Name . | Target . | egr-1 mRNA reduction rate ± SD (%) . | egr-3 mRNA reduction rate ± SD (%) . |
---|---|---|---|
DMSO | 0 | 0 | |
KDR nAb. | KDR | −81 ± 6.4* | −87 ± 5.7* |
LY294002 | PI3K | (superinduced by 60-fold) | −73 ± 2.4* |
PD98059 | MEK1/2 | −68 ± 2.3* | −78 ± 4.4* |
SB203580 | p38 | (superinduced by 10-fold) | N.E. |
Cyclosporine A | Calcineurin | N.E. | −75 ± 3.9* |
BAPTA-AM | Ca2+ | −87 ± 3.9 | −99 ± 0.1* |
GF109203X | PKCα, βI, βI, σ, γ, ϵ | −44 ± 1.9† | −99 ± 0.1* |
Gö6976 | PKCα, βI | −40 ± 5.4† | −99 ± 0.1* |
Rottlerin | PKCσ, θ | (superinduced by 10-fold) | −59 ± 3.2* |
SP600125 | JNK | −95 ± 2.1* | −99 ± 0.1* |
H-85 | PKA | (superinduced by 6-fold) | −73 ± 9.7* |
Cycloheximide | Protein biosynthesis | (superinduced by 120-fold) | (superinduced by 10-fold) |
Name . | Target . | egr-1 mRNA reduction rate ± SD (%) . | egr-3 mRNA reduction rate ± SD (%) . |
---|---|---|---|
DMSO | 0 | 0 | |
KDR nAb. | KDR | −81 ± 6.4* | −87 ± 5.7* |
LY294002 | PI3K | (superinduced by 60-fold) | −73 ± 2.4* |
PD98059 | MEK1/2 | −68 ± 2.3* | −78 ± 4.4* |
SB203580 | p38 | (superinduced by 10-fold) | N.E. |
Cyclosporine A | Calcineurin | N.E. | −75 ± 3.9* |
BAPTA-AM | Ca2+ | −87 ± 3.9 | −99 ± 0.1* |
GF109203X | PKCα, βI, βI, σ, γ, ϵ | −44 ± 1.9† | −99 ± 0.1* |
Gö6976 | PKCα, βI | −40 ± 5.4† | −99 ± 0.1* |
Rottlerin | PKCσ, θ | (superinduced by 10-fold) | −59 ± 3.2* |
SP600125 | JNK | −95 ± 2.1* | −99 ± 0.1* |
H-85 | PKA | (superinduced by 6-fold) | −73 ± 9.7* |
Cycloheximide | Protein biosynthesis | (superinduced by 120-fold) | (superinduced by 10-fold) |